Low-dose inhaled corticosteroid therapy and risk of emergency department visits for asthma

被引:84
作者
Sin, DD [1 ]
Man, SFP
机构
[1] Univ Alberta, Walter C Mackenzie Ctr 2E4 29, Div Pulm Med, Edmonton, AB T6G 2B7, Canada
[2] Inst Hlth Econ, Edmonton, AB, Canada
关键词
D O I
10.1001/archinte.162.14.1591
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Patients who visit the emergency department (ED) because of asthma frequently have a relapse. While the use of inhaled corticosteroids has been demonstrated to improve asthma symptoms and lung function, it is not clear whether their use after discharge from the ED reduces asthma relapse rates. Objective: To determine whether inhaled corticosteroid therapy reduces ED asthma relapse rates. Methods: We analyzed ED visit and medication data on patients 5 to 60 years of age who were enrolled in a government-sponsored drug plan and who visited an ED because of;asthma between April 1, 1997, and March 31, 1999, in Alberta, Canada (N=1293). Using a Cox proportional hazards model, we determined the relative risk (RR) of relapse ED visits among users and nonusers of inhaled corticosteroids after discharge from the ED. We also compared the RR of relapse ED visits across different dose categories. Results: Users of inhaled corticosteroids after ED discharge had 45% fewer relapse ED visits than did nonusers (adjusted RR, 0.55; 95% confidence interval [CI], 0.44-0.69). Low-, medium-, and high-dose therapies were associated with similar reductions in the risk of relapse ED visits: low-dose therapy (RR, 0.52; 95% CI, 0.39-0.68), medium-dose therapy (RR, 0.51; 95% CI, 0.34-0.76), and high-dose therapy (RR, 0.67; 95% CI, 0.47-0.94). Conclusions: Inhaled corticosteroid therapy after ED discharge is associated with a significant reduction in the risk of subsequent ED visits. Low-dose therapy appears to be as effective as high-dose therapy. However, further studies are needed to determine the optimal dosing regimen for inhaled corticosteroid therapy for asthma.
引用
收藏
页码:1591 / 1595
页数:5
相关论文
共 22 条
[1]  
Adams N., 2001, COCHRANE DB SYST REV, V1
[2]   DRUG-THERAPY - INHALED GLUCOCORTICOIDS FOR ASTHMA [J].
BARNES, PJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1995, 332 (13) :868-875
[3]  
Boulet LP, 1999, CAN MED ASSOC J, V161, pS1
[4]   MARKERS OF RISK OF ASTHMA DEATH OR READMISSION IN THE 12 MONTHS FOLLOWING A HOSPITAL ADMISSION FOR ASTHMA [J].
CRANE, J ;
PEARCE, N ;
BURGESS, C ;
WOODMAN, K ;
ROBSON, B ;
BEASLEY, R .
INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 1992, 21 (04) :737-744
[5]   Use of inhaled corticosteroids and the risk of cataracts [J].
Cumming, RG ;
Mitchell, P ;
Leeder, SR .
NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (01) :8-14
[6]   ADAPTING A CLINICAL COMORBIDITY INDEX FOR USE WITH ICD-9-CM ADMINISTRATIVE DATABASES [J].
DEYO, RA ;
CHERKIN, DC ;
CIOL, MA .
JOURNAL OF CLINICAL EPIDEMIOLOGY, 1992, 45 (06) :613-619
[7]   Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma [J].
Garbe, E ;
LeLorier, J ;
Boivin, JF ;
Suissa, S .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1997, 277 (09) :722-727
[8]   Association of inhaled corticosteroid use with cataract extraction in elderly patients [J].
Garbe, E ;
Suissa, S ;
LeLorier, J .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 280 (06) :539-543
[9]   Risk factors for death from asthma, chronic obstructive pulmonary disease, and cardiovascular disease after a hospital admission for asthma [J].
Guite, HF ;
Dundas, R ;
Burney, PGJ .
THORAX, 1999, 54 (04) :301-307
[10]   COMPARISON OF A BETA-2-AGONIST, TERBUTALINE, WITH AN INHALED CORTICOSTEROID, BUDESONIDE, IN NEWLY DETECTED ASTHMA [J].
HAAHTELA, T ;
JARVINEN, M ;
KAVA, T ;
KIVIRANTA, K ;
KOSKINEN, S ;
LEHTONEN, K ;
NIKANDER, K ;
PERSSON, T ;
REINIKAINEN, K ;
SELROOS, O ;
SOVIJARVI, A ;
STENIUSAARNIALA, B ;
SVAHN, T ;
TAMMIVAARA, R ;
LAITINEN, LA .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (06) :388-392